Result of AGM

RNS Number : 5670O

Open Orphan PLC

02 October 2019

 

02 October 2019

Open Orphan plc

("Open Orphan" or the "Company")

Result of AGM

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that all the resolutions put to shareholders at the Annual General Meeting of the Company held earlier today were duly passed.

Enquiries:

Open Orphan plc Tel: [phone]
Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: [phone]
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: [phone]
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: [phone]
Tom Huddart / Billy Clegg / Dan Sherwen

Notes to Editors:

Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services business. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

 

END

 

 

RAGUGGAAUUPBGCP